缰核痛相关神经元对伤害性刺激和吗啡的反应

目的:观察缰核痛相关神经元对经典镇痛药吗啡的反应,了解缰核的痛觉属性.方法:实验在浅麻醉下的成年大鼠进行.通过脑室插管微量注射,或经五管微电极电泳吗啡、纳络酮、八肽胆囊收缩素(CCK-8)等,并记录缰核内痛相关神经元的单位放电.结果:在内侧缰核、外侧缰核记录的痛相关神经元放电,又可分为痛兴奋性神经元和痛抑制性神经元.在缰核微电泳吗啡后,痛兴奋性神经元以抑制反应为主,痛抑制性神经元以兴奋反应为主.微电泳纳洛酮可以翻转吗啡对缰核的作用.在吗啡耐受大鼠腹腔注射吗啡10 mg/kg,LHb痛相关神经元表现为镇痛效应的数量远大于MHb痛相关神经元的,表明外侧缰核受吗啡的作用程度高于内侧缰核.对吗啡耐受大鼠脑室注入CCK拮抗剂后,再由腹腔注射吗啡,可减弱对吗啡的耐受程度.反之,在腹腔注射吗啡(10 mg/kg)10 min后,侧脑室注射CCK-8(15 ng/10μl),CCK-8可拮抗吗啡对LHb的镇痛作用,但对MHb的拮抗作用不明显.结论:缰核的痛兴奋性神经元和痛抑制性神经元对伤害性(痛)刺激敏感而不易发生适应.其中外侧缰核神经元对吗啡的敏感性高于内侧缰核神经元.     

缰核神经元阿片受体的分布特征

目的: 用膜片钳方法探索内侧缰核(MHb),外侧缰核(LHb)阿片受体的类型.方法: 急性分离出生后10～15 d的大鼠缰核神经元,用全细胞电压钳记录方式记录其K 通道电流.以DAGO(μ受体激动剂),DPDPE(σ受体激动剂)区分MHb,LHb分别含有的阿片受体类型.结果: 在缰核可记录到两种类型的K 通道,快(瞬时)整流 K 通道(IA)和慢(延时)整流 K 通道(IK).DAGO,DPDPE使两种类型的K 通道电流增加.结论: MHb有较高密度的σ受体的分布;LHb以μ受体类型分布为主.     

损毁缰核对应激性高血压形成的影响

目的和方法 :运用核团损毁和微量注射的方法观察损毁缰核 (Hb)对应激性高血压 (SIH)形成进程的影响及SIH大鼠Hb内神经元对L 谷氨酸 (Glu)反应性的变化。结果 :①损毁双侧Hb延缓了SIH的形成进程 ;②在SIH大鼠内侧Hb(MHb)微量注射不同浓度的CIu ,血压明显升高 ,呈浓度依赖性 ,升高值与正常大鼠MHb注入等量GIu引起的升高值相比 ,有显著性差异 (P <0 .0 5 ) ;③在SIH大鼠外侧Hb(LHb)注入不同浓度的Glu ,血压明显下降 ,也呈浓度依赖性 ,下降值与正常大鼠LHb注入等量Glu引起的下降值相比 ,有显著性差异 (P <0 .0 5 )。结论 :损毁Hb延缓了SIH的形成进程 ,SIH大鼠Hb对Glu的敏感性提高了 ,Hb参与SIH的形成 ,且其作用有部位特异性。     

刺激大鼠伏核和伏核内微量注射纳洛酮对外侧缰核“痛”单位放电的影响

在清醒、肌肉麻痹状态下的大鼠,观察到重复电刺激伏核对外侧缰核痛兴奋单位(LHPE)自发放电和痛诱发放电有明显的抑制作用。腹腔注射纳洛酮(6mg/kg体重)可阻断这种抑制作用。而电刺激伏核对外侧缰核痛抑制单位放电有兴奋作用。双侧伏核内微量注射纳洛酮(1.8ug,4min注完)使 LHPE 放电增加,注射吗啡(15ug,4min注完)可抑制 LHPE 放电。本文就以上结果在针刺镇痛中的意义进行了讨论。     

延髓腹侧结构在刺激缰核诱发升压反应中的作用

电刺激缰核(Hb)可使大鼠血压明显升高,但心率变化不明显。电刺激Hb血压升高的同时,延髓腹侧结构(VM)中46.5％的神经元自发放电频率增加,这些神经元分布在VM的升压神经元群中,41.9％的神经元自发放电频率降低,这些神经元分布在VM的降压神经元群中,11.6%的神经元自发放电频率不变,升压和降压神经元群中均有这种神经元。单侧损毁VM的网状旁巨细胞核后,动物血压基本不变,也不影响电刺激Hb引起的升压反应。双侧损毁VM的网状旁巨细胞核后,动物血压从98.4±11.2mmHg降至45.2±10.3mmHg,阻断了电刺激Hb引起的升压反应。单侧或双恻损毁疑核及部分延髓网状核腹侧后,动物血压基本不变,且不影响电刺激Hb引起的升压反应。 上述结果表明,Hb主要通过VM中升压神经元群的网状旁巨细胞核参与心血管活动的调节。     

刺激杏仁基底外侧核对外侧缰核神经元单位放电的影响

用玻璃微电极细胞外记录大鼠外侧缰核(LHN)神经元的单位放电。共记录了110个神经元。其中痛兴奋神经元(LHPE)75个;痛抑制神经元(LHPI)11个;广动力型神经元2个;无反应神经元17个;此外还有5个对躯体与内脏伤害性刺激反应不同的神经元。电刺激杏仁基底外侧核(以下简称杏仁核,AMG)对LHPE和LHPI的自发放电主要产生抑制作用,分别占总数的81.1％和72.7％,并抑制其对伤害性刺激的反应;对无反应神经元和广动力型神经元无明显影响。AMG内微量注射吗啡能抑制LHPE的伤害性刺激反应,但对其自发放电无明显影响。微量注射纳洛酮则可增加LHPE的自发放电频率,并加强其对伤害性刺激的反应。注射纳洛酮还可以取消电针对LHPE的伤害性刺激反应的抑制作用。     

可卡因对大鼠痛阈和缰核痛相关神经元放电的影响

目的：观察可卡因对痛阈和LHb痛相关神经元放电的影响。方法：皮下注射不同剂量可卡因,观察大鼠痛阈的变化;用玻璃微电极记录静脉注射可卡因前后,Hb神经元对伤害性刺激的反应。结果：低剂量可卡因降低大鼠痛阈;高剂量可卡因提高大鼠痛阈。静脉注射可卡因后,LHb痛兴奋单位自发放电增加,对痛的兴奋反应加强;LHb痛抑制单位自发放电减少,对痛的抑制反应减弱。结论：低剂量可卡因降低痛阈,同时提高LHb痛相关神经元的敏感性。     

褪黑色素对缰核痛神经元单位放电的影响及可能机制

目的通过观察褪黑色素对缰核痛神经元单位放电的影响,进一步证明褪黑色素的中枢镇痛作用及可能机制。方法：应用细胞外神经元单位放电记录方法,记录缰核神经元痛相关神经元放电,并观察外侧缰核痛神经元在褪黑色素作用下电活动的改变,及对伤害性刺激痛敏感性的改变,在此基础上观察纳洛酮的翻转作用。结果：褪黑色素影响外侧缰核痛神经元的电活动,并使外侧缰核痛神经元对伤害性刺激敏感性降低,此种作用可被纳洛酮翻转。结论：褪黑色素可通过作用于外侧缰核的阿片受体而影响其痛相关神经元对痛刺激的反应,这可能是褪黑色素中枢镇痛机制之一。     

电刺激大鼠扣带前回对血压和心率的影响

电刺激大鼠扣带前回(ACg),血压升高,心率加快,同时缰核(Hb)内20.7％的神经元兴奋,22.4％的神经元抑制,56.9％的神经元无反应。双侧Hb内微量注射盐酸利多卡因,可明显阻断电刺激ACg引起的心血管反应。结果表明,ACg对心血管活动的调节,一部分是通过改变Hb的活动来实现的,Hb是ACg调节心血管活动的下行性通路之一。     

大鼠下丘脑-缰核系统对中缝大核痛反应神经元放电的影响

在大鼠尾部给以伤害性刺激后,外侧缰核和中缝大核的单位按其反应型式可分为四种类型,即痛兴奋单位、广动力型单位、痛抑制单位和无反应单位。电刺激下丘脑外侧区对外侧缰核中各种单位的自发放电主要产生抑制作用,对其中痛兴奋单位和痛抑制单位的自发放电尤为明显。刺激下丘脑外侧区对中缝大核中痛兴奋单位的自发放电有明显兴奋作用,刺激外侧缰核则有抑制作用,损毁外侧缰核后,下丘脑外侧区的兴奋作用消失。分别刺激下丘脑外侧区和外侧缰核对中缝大核中痛抑制单位的自发放电都有明显的抑制作用;损毁外侧缰核后下丘脑外侧区的抑制作用仍存在。以上结果提示,下丘脑外侧区影响中缝大核活动的途径有二。其一可能是通过去除外侧缰核对中缝大核中痛兴奋单位的紧张性抑制作用;另外还可能通过外侧缰核以外的途径抑制中缝大核中痛抑制单位的活动。     

Ultrastructural features and acetylcholinesterase histochemistry of the rat habenular complex

The ultrastructural features and the acetylcholinesterase (AChE) localization of the rat habenula have been studied. On the basis of different morphology and AChE content, it is suggested that at least two types of neurons are present in the medial habenula (MHb) and three types of neurons in the lateral habenula (LHb). In particular, actively AChE-synthesizing neurons have been noticed in both LHb and MHb. Some unusual ultrastructural arrangements of the endoplasmic reticulum have been described in habenular neurons. Finally, the most common types of synaptic contacts present in the habenular complex have been surveyed.     

Inhibition of locus coeruleus neuronal activity by beta-phenylethylamine

The effect of beta-phenylethylamine (PEA) on brain noradrenaline (NA) neurons in the rat locus coeruleus (LC) was analyzed using single unit recording techniques including microiontophoretic methodology. Systemic injection of low doses of PEA consistently produced an instantaneous and dose-dependent inhibition of firing rate of the LC neurons. The effect was strongly antagonized by administration of the alpha 2-receptor antagonist yohimbine (1 mg/kg, i.v.) or by depletion of endogenous stores of NA by pretreatment with reserpine (10 mg/kg, i.p., 6 h), but unaffected by inhibition of tyrosine hydroxylase (alpha-met-hyl-p-tyrosine (alpha-MT), 250 mg/kg, i.p., 30 min). In contrast, the inhibitory effect of PEA on the LC neurons was strongly potentiated by pretreatment with the selective monoamine oxidase (MAO) - B inhibitor pargyline (2 mg/kg, i.p., 1 h), but, unexpectedly, also by pretreatment with the MAO-A selective inhibitors clorgyline (2 mg/kg, i.p., 1 h) or FLA 336 (2 mg/kg, i.p., 1 h). When microiontophoretically applied directly onto the LC neurons, PEA produced inhibition of a majority of the NA neurons. This action was prevented by intravenous injection of yohimbine (2.5 mg/kg). The results suggests that the action of PEA on NA neurons in the LC is an indirect effect, requiring availability of a reserpine-sensitive storage pool of NA, and mediated via activation of central alpha 2-receptors within the LC.     

Amphetamine-induced inhibition of central noradrenergic neurons: a pharmacological analysis

The amphetamine-induced inhibition of brain noradrenaline (NA) containing neurons in the rat locus coeruleus (LC) was pharmacologically analyzed utilizing single unit recording techniques. The presynaptic α-receptor blocking agent yohimbine (10 mg/kg i.p., 30 min before) largely prevented the amphetamine-induced depression of LC units in contrast to prazosin (0.6 mg/kg i.p., 30 min) or phenoxybenzamine (20 mg/kg, 30 min) which both slow preference for postsynaptic α-receptors. The β-receptor blocking agent, propranolol (10 mg/kg, 30 min), as well as the peripherally but not centrally active α-receptor blocking drug phentolamine (10 mg/kg, i.p., 30 min), also did not block the amphetamine effect. The LC inhibition by amphetamine was blocked by pretreatment with reserpine (10 mg/kg, i.p., 5 h), which caused almost total depletion of brain catecholamines. However, unlike the amphetamine-induced inhibition of central dopamine (DA) neurons the NA cell inhibition was not blocked by pretreatment with a tyrosine hydroxylase inhibitor (α-MT, 50 or 250 mg/kg i.p., 30 min). These results suggest that the amphetamine-induced inhibition of NA neurons in the LC is an indirect effect, mediated via activation of central α-receptors of presynaptic character. The lack of antagonism by α-MT indicate that the NA release by amphetamine, unlike its effect on brain DA, is not critically dependent on the rate of tyrosine hydroxylation. Thus the euphoriant action of amphetamine, which is blocked by α-MT, may be associated with release of DA rather than NA in brain.     

Complex role of 5-HT in the regulation of TSH secretion in the male rat

The role of 5-hydroxytryptamine (5-HT) in the regulations of TSH secretion was studied in male rats using both peripheral and central administration of the drugs. Basal TSH levels were not modified by moderate doses of 5-HT (subcutaneously) or its precursors or antagonists (intraperitoneally) given 1 h before decapitation. The cold-stimulated TSH secretion was decreased by L-tryptophan (L-TRP, 400 mg/kg i.p.), quipazine (10 mg/kg i.p.) and 5-HT (1 or 5 mg/kg s.c. or i.v.) as well as by p-chlorophenylalanine (pCPA, 20 or more mg/kg i.p.) when the drugs were given 1 h before sampling. pCPA (100-400 mg/kg i.p.) was active 24-48 h after the injection but repetitive administration did not affect TSH levels. 5-HT (5 mg/kg s.c.) was effective also in pinealectomized animals. L-TRP and 5-hydroxytryptophan potentiated the TRH-stimulated TSH secretion when given 1 h before killing. 5-HT (10 microgram/rat) infused into the third ventricle enhanced the cold-stimulated TSH secretion when given 30-45 min before sampling. When injected into the medial basal hypothalamus, 50-HT (1-10 microgram/rat) had no effect on basal or stimulated TSH levels. The results suggest: (1) 5-HT does not play any role in the regulation of basal TSH secretion; (2) in the cold-stimulated TSH secretion 5-HT has a stimulatory action evidently inside the blood-brain barrier and also an inhibitory effect obviously outside this barrier.     

Anaphe venata larva extract-induced purposeless chewing in rats: the role of cholinergic, GABAergic and opioid systems

Seasonal ataxia was reported in humans following the consumption ofAnaphe venata larva as protein supplement in diet and altered motor function in rodents when the extract was administered intraperitoneally. In this study we investigated the effect of the crude aqueous and Phosphate Buffer Saline (PBS) extracts of this larva on altered spontaneous rat behavior in a novel environment particularly chewing behaviour, with a view to determine the mechanism(s) involved in these behavioural alteration. Animals were randomly assigned into four groups (n = 6-12 per group) and graded doses of aqueous and PBS extracts (100-400 mg/kg) were administered dissolved in saline intraperitoneally (i.p.) to each animal in the experimental groups. The control group received an equivalent volume of saline. Behavioral scores were recorded for a period of 30 minutes after the administration of saline or extract. The role of various receptors in the extract induced chewing was evaluated using known receptor agonist/antagonists. Results revealed a significant increase in purposeless chewing (F (7, 95) = 7.85; p <0.05) by the aqueous extract compared to saline control at all dose levels, which was significantly attenuated by scopolamine (3 mg/kg, i.p) and thiamine (1 mg/kg, i.p) respectively (p <0.05); while flumazenil (2 mg/kg, i.p) and naloxone (2.5 mg/kg, i.p) did not alter the induced purposeless chewing behaviour. Also, administration of PBS induced a significant (F (7, 95) = 6.11; p <0.05) increase in chewing behaviour but only at 400 mg/kg dose level which was attenuated by scopolamine (3 mg/kg, i.p); while flumazenil (2 mg/kg, i.p), naloxone (2.5 mg/kg, i.p), and thiamine (1 mg/kg, i.p) potentiated purposeless chewing behaviour respectively. It may therefore be concluded from this study that Anaphe extract-induced purposeless chewing behaviour in rat is mediated via the activation of cholinergic neurotransmission which is modulated by GABAergic and opioid receptor systems.     

Losartan and acute myocardial infarction in insulin-resistant Zucker fatty rats: reduced ventricular arrhythmias and improved survival

Insulin resistance (IR) and diabetes increase the risk of acute myocardial infarction (MI). Angiotensin receptor blockers (ARBs) have been shown to reduce the risk of cardiovascular events in patients with hypertension and diabetes, and to be beneficial after a large MI. Whether pretreatment with ARBs is beneficial in acute MI is unknown. We evaluated whether pre-, peri-, and post-MI treatment with the ARB losartan improved the outcome in the IR Zucker fatty rat (ZFR). ZFR (n=264) received either losartan (3 mg/kg daily) or vehicle for 7 d prior to MI. Early (24 h) protocol (n=31): ventricular arrhythmias were evaluated post-MI using continuous ambulatory ECG monitoring. Late (38 d) protocol (n=233): losartan was increased to 10 mg/kg daily 10 d post-MI and to 30 mg/kg daily 20 d post-MI. Blood glucose, cardiac hemodynamics and remodeling, GLUT-4, fetal gene expression, and survival were evaluated. In large-MI rats, losartan improved early survival (43% vs. 27% in controls, p=0.01) and late survival (23% vs.15% in controls, p=0.02). Improved early survival was associated with a reduction in ventricular arrhythmias. Losartan reduced pulmonary congestion, cardiac hypertrophy, and fetal gene expression in the absence of statistically significant changes in ventricular dilatation and hemodynamics. Blood glucose and cardiac GLUT-4 expression did not change with losartan. In IR ZFR, losartan improves post-MI survival, likely as a result of an early reduction in ventricular arrhythmias. There was also an associated reduction in pulmonary congestion, hypertrophy, and fetal gene expression.     

Enhanced angiotensin II-mediated central sympathoexcitation in streptozotocin-induced diabetes: role of superoxide anion

Studies have shown that the superoxide mechanism is involved in angiotensin II (ANG II) signaling in the central nervous system. We hypothesized that ANG II activates sympathetic outflow by stimulation of superoxide anion in the paraventricular nucleus (PVN) of streptozotocin (STZ)-induced diabetic rats. In α-chloralose- and urethane-anesthetized rats, microinjection of ANG II into the PVN (50, 100, and 200 pmol) produced dose-dependent increases in renal sympathetic nerve activity (RSNA), arterial pressure (AP), and heart rate (HR) in control and STZ-induced diabetic rats. There was a potentiation of the increase in RSNA (35.0 ± 5.0 vs. 23.0 ± 4.3%, P < 0.05), AP, and HR due to ANG II type I (AT(1)) receptor activation in diabetic rats compared with control rats. Blocking endogenous AT(1) receptors within the PVN with AT(1) receptor antagonist losartan produced significantly greater decreases in RSNA, AP, and HR in diabetic rats compared with control rats. Concomitantly, there were significant increases in mRNA and protein expression of AT(1) receptor with increased superoxide levels and expression of NAD(P)H oxidase subunits p22(phox), p47(phox), and p67(phox) in the PVN of rats with diabetes. Pretreatment with losartan (10 mg·kg(-1)·day(-1) in drinking water for 3 wk) significantly reduced protein expression of NAD(P)H oxidase subunits (p22(phox) and p47(phox)) in the PVN of diabetic rats. Pretreatment with adenoviral vector-mediated overexpression of human cytoplasmic superoxide dismutase (AdCuZnSOD) within the PVN attenuated the increased central responses to ANG II in diabetes (RSNA: 20.4 ± 0.7 vs. 27.7 ± 2.1%, n = 6, P < 0.05). These data support the concept that superoxide anion contributes to an enhanced ANG II-mediated signaling in the PVN involved with the exaggerated sympathoexcitation in diabetes.     

分别兴奋大鼠内侧和外侧缰核引起痛阈的不同改变

（Ｈｂ）与痛觉调制有关,但不同实验室的结果并不一致,本实验目的在于澄清其中原因,实验在戊巴比妥钠浅麻和清醒的大鼠上进行,应用玻璃微电极微量注射Ｌ－谷氨酸（Ｌ－Ｇｌｕ）到内侧缰核（ＭＨｂ）和外侧缰核（ＬＨｂ）,利用多种动物模型观察大鼠的痛阈改变,实验结果发现,兴奋ＭＨｂ时痛阈增高,而ＬＨｂ兴奋时痛阈降低。     

Rubiscolin-6, a delta opioid peptide derived from spinach Rubisco, has anxiolytic effect via activating sigma1 and dopamine D1 receptors

Rubiscolin-6 (Tyr-Pro-Leu-Asp-Leu-Phe) is a delta opioid peptide derived from the large subunit of spinach d-ribulose-1,5-bisphosphate carboxylase/oxygenase (Rubisco). We previously reported that rubiscolin-6 had an analgesic effect and stimulated memory consolidation. Here we show that intraperitoneally (i.p.) or orally administered rubiscolin-6 has an anxiolytic effect at a dose of 10 mg/kg or 100 mg/kg, respectively, in the elevated plus-maze test in mice. The anxiolytic effects of rubscolin-6 after i.p. (10 mg/kg) and oral (100 mg/kg) administration were blocked by a delta opioid receptor antagonist, naltrindole (1 mg/kg, s.c.), suggesting that the anxiolytic activity of rubiscolin-6 is mediated by delta opioid receptor. The anxiolytic effect of rubiscolin-6 (10 mg/kg, i.p.) was also blocked by a dopamine D(1) antagonist, SCH23390 (30 microg/kg, i.p.), but not by a dopamine D(2) antagonist, raclopride (15 microg/kg, i.p.). The anxiolytic effect of rubiscolin-6 (10 mg/kg, i.p.) was blocked by sigma(1) receptor antagonist, BMY14802 (0.5 mg/kg, i.p.) or BD1047 (10 mg/kg, i.p.). Taken together, the anxiolytic effect of rubiscolin-6 is mediated by sigma(1) and dopamine D(1) receptors downstream of delta opioid receptor.     

Leptin inhibits gastric emptying in rats: role of CCK receptors and vagal afferent fibers

Leptin regulates energy homeostasis and body weight by balancing energy intake and expenditure. It was recently reported that leptin, released into the gut lumen during the cephalic phase of gastric secretion, is capable of initiating intestinal nutrient absorption. Vagal afferent neurons also express receptors for both CCK and leptin, which are believed to interact in controlling food intake. The present study was undertaken to investigate the central and peripheral effects of leptin on gastric emptying rate. Under anesthesia, male Sprague-Dawley rats (250-300 g) were fitted with gastric Gregory cannulas (n=12) and some had additional cerebroventricular cannulas inserted into their right lateral ventricles. Following recovery, the rate of gastric emptying of saline (300 mOsm/kg H(2)O) was determined after instillation into the gastric fistula (3 ml, 37 degrees C, containing phenol red, 60 mg/l as a non-absorbable dilution marker). Gastric emptying rate was determined from the volume and phenol red concentrations recovered after 5 min. Leptin, injected intraperitoneally (i.p.; 10, 30, 60, 100 microg/kg) or intracerebroventricularly (i.c.v.; 5, 15 microg/rat) 15 min before the emptying, delayed gastric emptying rate of saline at the dose of 30 microg/kg or 15 microg/rat (p<0.001). When CCK(1) receptor blocker L-364,718 (1 mg/kg, i.p.), CCK(2) receptor blocker L-365,260 (1 mg/kg, ip) or adrenergic ganglion blocker bretylium tosylate (15 mg/kg, i.p.) was administered 15 min before ip leptin (30 microg/kg) injections, leptin-induced delay in gastric emptying was abolished only by the CCK(1) receptor blocker (p<0.001). However, the inhibitory effect of central leptin on gastric emptying was reversed by adrenergic blockade, but not by either CCK antagonists. Our results demonstrated that leptin delays gastric emptying. The peripheral effect of leptin on gastric motility appears to be mediated by CCK(1) receptors, suggesting the release of CCK and the involvement of vagal afferent fibers. On the other hand, the central effect of leptin on gastric emptying is likely to be mediated by adrenergic neurons. These results indicate the existence of a functional interaction between leptin and CCK receptors leading to inhibition of gastric emptying and short-term suppression of food intake, providing an additional feedback control in producing satiety.